Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT
- 1 November 2019
- journal article
- research article
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 23 (62), 1-94
- https://doi.org/10.3310/hta23620
Abstract
Health Technology Assessment Volume: 23, Issue: 62, Published in November 2019Keywords
Funding Information
- Health Technology Assessment Programme (08/116/69)
This publication has 45 references indexed in Scilit:
- Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcomeBMC Medical Research Methodology, 2013
- Time-dependent endpoints as predictors of overall survival in multiple myelomaBMC Cancer, 2013
- Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapyCochrane Database of Systematic Reviews, 2012
- Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsHaematologica, 2011
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective studyBlood, 2009
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaLeukemia, 2008
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Antibiotic prophylaxis in neutropenic patientsCancer, 2006
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958